Research progress on non-protein-targeted drugs for cancer therapy

Zhang, Yiwen; Lu, Lu; Song, Feifeng; Zou, Xiaozhou; Liu, Yujia; Zheng, Xiaowei; Qian, Jinjun; Gu, Chunyan; Huang, Ping; Yang, Ye

doi:10.1186/s13046-023-02635-y

Journal of Experimental & Clinical Cancer Research

Table 2 Antisense oligonucleotides cancer therapeutics in clinal trials

From: Research progress on non-protein-targeted drugs for cancer therapy

Target	Drug name	Cancer	ClinicalTrials. gov Identifier	Current status
Bcl-2	Oblimersen	Solid tumors	NCT00543231	Phase I completed
	Oblimersen	Solid tumors	NCT00636545	Phase I completed
	Oblimersen plus carboplatin and paclitaxel	Advanced solid tumors	NCT00054548	Phase I completed
	Oblimersen plus etoposide and carboplatin	Lung cancer	NCT00017251	Phase I completed
	Olimersen plus paclitaxel	Lung cancer	NCT00005032	Phase I/II completed
	Olimersen plus Irinotecan	Colorectal cancer	NCT00004870	Phase I/II completed
	Oblimersen	CLL	NCT00021749	Phase I/II completed
	Oblimersen plus rituximab and fludarabine	CLL	NCT00078234	Phase I/II completed
	Oblimersen plus doxorubicin and docetaxel	Metastatic or locally advanced breast cancer	NCT00063934	phase I/II terminated
	Oblimersen plus docetaxel	Prostate cancer	NCT00085228	phase II completed
	Oblimersen with interferon alfa	mRCC	NCT00059813	Phase II completed
	Oblimersen plus dacarbazine	Melanoma	NCT00016263	Phase III completed
	Oblimersen plus dexamethasone	Multiple myeloma, plasma cell neoplasm	NCT00017602	Phase III completed
	Oblimersen plus fludarabine and cyclophosphamide	CLL	NCT00024440	Phase III completed
	BP1002	Advanced lymphoid malignancies	NCT04072458	Phase I recruiting
Grb2	BP1001 with or without LDAC	AML, CML, ALL, MDS	NCT01159028	Phase I completed
	BP1001-A plus paclitaxel	Advanced or recurrent solid tumors	NCT04196257	Phase I recruiting
	BP1001 plus ventoclax and decitabine	AML	NCT02781883	Phase II recruiting
CLU	OGX-011 with hormone therapy	Prostate cancer	NCT00054106	Phase I completed
	OGX-011 plus docetaxel	Metastatic or locally recurrent solid tumors	NCT00471432	Phase I completed
	OGX-011 plus docetaxel	Breast cancer	NCT00258375	Phase II completed
	OGX-011 plus docetaxel/prednisone	mCRPC	NCT01188187	Phase III completed
	OGX-011 plus docetaxel/prednisone	mCRPC	NCT01578655	Phase III completed
Hsp27	OGX-427 plus docetaxel	Neoplasms	NCT00487786	Phase I completed
	OGX-427	CRPC	NCT01120470	Phase II completed
	OGX-427 plus docetaxel	Relapsed or refractory metastatic bladder cancer	NCT01780545	Phase II completed
STAT3	AZD9150 plus Durvalumab	Diffuse large B-cell lymphoma	NCT02549651	Phase I completed
	AZD9150	Advanced cancers	NCT01563302	Phase I/II completed
	AZD9150	Advanced or metastatic hepatocellular carcinoma	NCT01839604	Phase I/Ib completed
	AZD9150	Malignant ascites	NCT02417753	Phase II Terminated (Could not find these types of patients)
Raf-1	LErafAON	Advanced cancer	NCT00100672	Phase I completed
	LErafAON	Advanced solid tumors	NCT00024661	Phase I completed
	LErafAON plus radiotherapy	Neoplasms	NCT00024648	Phase I completed
Raf-1/Pkc-α	ISIS 5132 plus ISIS 3521	Matastatic breast cancer	NCT00003236	Phase II completed
HIF-1α	EZN-2968	Neoplasms, liver metastases	NCT01120288	Phase I completed
	EZN-2968	Advanced solid tumors or lymphoma	NCT00466583	Phase I completed
	EZN-2968	HCC	NCT02564614	Phase I completed
	AZD4785	Advanced solid tumors	NCT03101839	Phase I completed
AR	AZD5312	Advanced solid tumors with AR pathway as a potential factor	NCT02144051	Phase I completed
c-myb	c-myb AS ODN	Hematologic malignancies	NCT00780052	Phase I completed
R2 component of mRNA	GTI-2040 plus capecitabine	mRCC	NCT00056173	Phase I/II completed
XIAP	AEG35156 plus paclitaxel	Advanced breast cancer	NCT00558545	phase I/II terminated (Avastin approved for first-in-line treatment)
XIAP	AEG35156 plus gemcitabine	Advanced pancreatic cancer	NCT00557596	Phase I/II terminated
TGF-β2	TASO-001	Solid tumor	NCT04862767	Phase I recruiting
Akt-1	WGI-0301	Advanced solid tumors	NCT05267899	Phase I recruiting
FOXP3	AZD8701 plus durvalumab	Advanced solid tumors	NCT04504669	Phase I recruiting

Bcl-2 B-cell lymphoma 2, Grb-2 growth factor receptor-bound protein-2, CLU clusterin, Hsp27 Heat shock protein 27, STAT3 signal transduction and transcriptional activator 3, PKC-α protein kinase C-alpha, HIF-1 hypoxia-inducible factor-1, AR androgen receptor, XIAP X-linked inhibitor of apoptosis, TGF-β2 transforming growth factor beta 2, FOXP3 forkhead box P3, CLL chronic lymphocytic leukemia, mRCC metastatic renal cell cancer, AML acute myeloid leukemia, CML chronic myelogenous leukemia, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndrome, mCRPC metastatic castrate resistant prostate cancer, CRPC castrate resistant prostate cancer, HCC hepatocellular carcinoma

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com